Development and validation of a pharmacy migraine questionnaire to assess suitability for treatment with a triptan

Table 3 Analysis of the pharmacist assessment of suitability

Measure	UK study^a (n = 439)		Australian study^a (n = 456)		German study^a (n = 458)
Measure	Value	95% CI	Value	95% CI	Value	95% CI
False-positive rate	39/195 = 0.200	0.144, 0.256	26/156 = 0.167	0.108, 0.225	48/309 = 0.155	0.115, 0.196
Specificity	83/122 = 0.680	0.598, 0.763	79/105 = 0.752	0.670, 0.835	39/87 = 0.448	0.344, 0.553
Positive predictive value	156/195 = 0.800	0.744, 0.856	130/156 = 0.833	0.775, 0.892	261/309 = 0.845	0.804, 0.885
Sensitivity	156/317 = 0.492	0.437, 0.547	130/351 = 0.370	0.320, 0.421	261/371 = 0.704	0.657, 0.750
Negative predictive value	83/244 = 0.340	0.281, 0.400	79/300 = 0.263	0.213, 0.313	39/149 = 0.262	0.191, 0.332

^aSumatriptan 50 mg for the studies in the UK and Australia; naratriptan 2.5 mg in Germany

ISSN: 1129-2377